Literature DB >> 17598825

Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma.

Daniel J Brat1, Bernd W Scheithauer, Gregory N Fuller, Tarik Tihan.   

Abstract

The 4(th) edition of the WHO Classification of Tumours of the Nervous System (WHO 2007) introduces changes that reflect both the recognition of new brain tumour types and a better understanding of neoplastic behavior. Three new tumours, angiocentric glioma (AG), pilomyxoid astrocytoma (PMA), and pituicytoma are added to the section on gliomas. AG is a slowly growing cerebral tumour that typically presents with seizures in children and young adults. It is characterized by monomorphous, bipolar tumour cells with a striking perivascular growth pattern. Although the 'cell of origin' of AG is not clear, ultrastructural evidence points to an ependymal derivation. Typically, AG can be cured by total resection, and is designated WHO grade I. PMA is a solid, circumscribed tumour occurring mainly in the hypothalamic region of young children. It is composed of a monomorphous population of bipolar tumour cells within a rich myxoid background, with a conspicuous anglocentric arrangement. While PMA is considered a more aggressive variant of pilocytic astrocytoma, this relationship awaits further clarification. The PMA has been designated WHO grade II. The pituicytoma, involves the posterior pituitary and/or its stalk and affects adults. It is solid in architecture, composed of spindle cells and presumably derived from pituicytes. Pituicytomas are indolent tumours, and are designated WHO grade I.

Entities:  

Mesh:

Year:  2007        PMID: 17598825     DOI: 10.1111/j.1750-3639.2007.00082.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  50 in total

1.  Case of pituicytoma in childhood.

Authors:  Ömer Yilmaz; Aynur Turan; Hasan Yiğit; Mahmut Duymuş; Uğur Koşar
Journal:  Childs Nerv Syst       Date:  2011-11-18       Impact factor: 1.475

Review 2.  The new World Health Organization Classification of Central Nervous System Tumors: what can the neuroradiologist really say?

Authors:  A G Osborn; K L Salzman; M M Thurnher; J H Rees; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2011-08-11       Impact factor: 3.825

3.  High accuracy of arterial spin labeling perfusion imaging in differentiation of pilomyxoid from pilocytic astrocytoma.

Authors:  S A Nabavizadeh; R Assadsangabi; M Hajmomenian; M Santi; A Vossough
Journal:  Neuroradiology       Date:  2015-02-10       Impact factor: 2.804

4.  Pituicytoma and isolated ACTH deficiency.

Authors:  John J Orrego
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  A case of angiocentric glioma with unusual clinical and radiological features.

Authors:  Gyung-Jun Rho; Hyojoon Kim; Hyoung-Ihl Kim; Myoung-Jin Ju
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

Review 6.  Pituicytoma: overview of treatment strategies and outcome.

Authors:  Ariyan Pirayesh Islamian; Rolf Buslei; Wolfgang Saeger; Rudolf Fahlbusch
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

7.  Pituicytoma: A report of three cases and literature review.

Authors:  Xiaoyu Yang; Xiaoliang Liu; Wensen Li; Dawei Chen
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

8.  Central nervous system tumors in the first year of life: a clinical and pathologic experience from a single cancer center.

Authors:  Maysa Al-Hussaini; Maisa Swaidan; Usama Al-Jumaily; Awni Musharbash
Journal:  Childs Nerv Syst       Date:  2013-03-24       Impact factor: 1.475

9.  [WHO classification of tumours of the CNS: revised edition of 2007 with critical comments on the typing und grading of common-type diffuse gliomas].

Authors:  S Feiden; W Feiden
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

10.  Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.

Authors:  Clovis Orlando da Fonseca; Rafael Linden; Débora Futuro; Cerli Rocha Gattass; Thereza Quirico-Santos
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-07-29       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.